Plasma half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
=== Selected books === Diagnosis and Management of Renal Disease and Hypertension (1988) ISBN 9780812111293 Immunohistology in Diagnostic Pathology (1989) ISBN 9780849349874 Non-neoplastic Kidney Diseases (2005) ISBN 9781881041962 Primer on Kidney Diseases (2009) ISBN 9781416051855 Fundamentals of Renal Pathology (2013) ISBN 9783642390791 Heptinstall's Pathology of the Kidney (2024) ISBN 9781975161538
==== Message-passing based approximations to the linear programming dual ==== ILP solvers depend on linear programming (LP) algorithms, such as the Simplex or barrier-based methods to perform the LP relaxation at each branch. These LP algorithms were developed as general-purpose optimization methods and are not optimized for the protein design problem (Equation (1)). In consequence, the LP relaxation becomes the bottleneck of ILP solvers when the problem size is large. Recently, several alternatives based on message-passing algorithms have been designed specifically for the optimization of the LP relaxation of the protein design problem. These algorithms can approximate both the dual or the primal instances of the integer programming, but in order to maintain guarantees on optimality, they are most useful when used to approximate the dual of the protein design problem, because approximating the dual guarantees that no solutions are missed. Message-passing based approximations include the tree reweighted max-product message passing algorithm, and the message passing linear programming algorithm.
== Research == Baclofen is being studied for the treatment of alcoholism. Evidence as of 2019 is not conclusive enough to recommend its use for this purpose. In 2014, the French drug agency ANSM issued a three-year temporary recommendation allowing the use of baclofen in alcoholism. In 2018, baclofen received a Marketing Authorization for use in alcoholism treatment from the agency if all other treatments are not effective. It is being studied along with naltrexone and sorbitol for Charcot–Marie–Tooth disease (CMT), a hereditary disease that causes peripheral neuropathy. It is also being studied for cocaine addiction. Baclofen and other muscle relaxants are being studied for potential use for persistent hiccups. From 2014 to 2017, baclofen misuse, toxicity and use in suicide attempts among adults in the US increased. In his 2008 book, Le Dernier Verre (translated literally as The Last Glass or The End of My Addiction), French-American cardiologist Olivier Ameisen described how he treated his alcoholism with baclofen. Inspired by this book, an anonymous donor gave $750,000 to the University of Amsterdam in the Netherlands to initiate a clinical trial of high-dose baclofen, which Ameisen had called for since 2004. The researchers concluded, "In summary, the current study did not find evidence of a positive effect of either low or high doses of baclofen in AD patients. However, we cannot exclude the possibility that baclofen is an effective medication for the treatment of severe, heavy drinking AD patients not responding to or not accepting routine psychosocial interventions."
In late 1807, Spanish and Napoleonic forces threatened the security of continental Portugal, causing Prince Regent John, in the name of Queen Maria I, to move the royal court from Lisbon to Rio de Janeiro. There they established some of Brazil's first financial institutions, such as its local stock exchanges and its National Bank, additionally ending the Portuguese monopoly on Brazilian trade and opening Brazil's ports to other nations. In 1809, in retaliation for being forced into exile, the Prince Regent ordered the conquest of French Guiana. With the end of the Peninsular War in 1814, the courts of Europe demanded that Queen Maria I and Prince Regent John return to Portugal, deeming it unfit for the head of an ancient European monarchy to reside in a colony. In 1815, to justify continuing to live in Brazil, where the royal court had thrived for six years, the Crown established the United Kingdom of Portugal, Brazil and the Algarves, thus creating a pluricontinental transatlantic monarchic state. However, the leadership in Portugal, resentful of the new status of its larger colony, continued to demand the return of the court to Lisbon (see Liberal Revolution of 1820). In 1821, acceding to the demands of revolutionaries who had taken the city of Porto, John VI departed for Lisbon. There he swore an oath to the new constitution, leaving his son, Prince Pedro de Alcântara, as Regent of the Kingdom of Brazil.
In addition, the Kanji of the Year (kotoshi no kanji) has been selected since 1995, and both the kanji and the word/phrase of the year often reflect current Japanese events and attitudes. For example, in 2011, following the Fukushima nuclear disaster, the frustratingly enigmatic phrase used by Japanese officials before the explosion regarding the possibility of a meltdown - "the possibility of recriticality is not zero" (Sairinkai no kanōsei zero de wa nai) - became the top phrase of the year. In the same year, the kanji for "bond" (i.e., family ties or friendship) became the kanji of the year, expressing the importance of collectiveness in the face of disaster. Liechtenstein: Word of the year (Liechtenstein) since 2002. In Norway, the Word of the year poll has been carried out since 2012. In Portugal, the Word of the year poll has been carried out since 2009. In Russia, the Word of the year poll has been carried out since 2007. In Slovenia, the word of the year poll has been carried out since 2016. Each year, it is announced in January together with the SSL (Slovenian Sign Language) gesture of the year. In Spain, a Word of the year has been selected by Fundéu since 2013. Switzerland: Word of the year (Switzerland), since 2003. In Ukraine, the Word of the year poll has been carried out since 2013. In The Netherlands, a word of the year poll is carried out by dictionary publisher Van Dale since 2007.
Sources: en.wikipedia.org
== Functions == Riboflavin is essential to the formation of two major coenzymes, FMN and FAD. These coenzymes are involved in energy metabolism, cell respiration, antibody production, growth and development. Riboflavin is essential for the metabolism of carbohydrates, protein and fats. FAD contributes to the conversion of tryptophan to niacin (vitamin B3) and the conversion of vitamin B6 to the coenzyme pyridoxal 5'-phosphate requires FMN. Riboflavin is involved in maintaining normal circulating levels of homocysteine; in riboflavin deficiency, homocysteine levels increase, elevating the risk of cardiovascular diseases.
=== Powder blending === In the pharmaceutical industry, a wide range of excipients may be blended together with the active pharmaceutical ingredient to create the final blend used to manufacture the solid dosage form. The range of materials that may be blended (excipients, API), presents a number of variables which must be addressed to achieve target product quality attributes. These variables may include the particle size distribution (including aggregates or lumps of material), particle shape (spheres, rods, cubes, plates, and irregular), presence of moisture (or other volatile compounds), particle surface properties (roughness, cohesion), and powder flow properties.
=== BMSS Medal === In 2002 the BMSS Medal was established by the society “to recognise sustained contributions by individual members of the British Mass Spectrometry Society to the development of mass spectrometry, primarily within the UK.”
Other bands that have been influenced by Alice in Chains include 10 Years, Avenged Sevenfold, Breaking Benjamin, Bush, Creed, Dallas Green, Days of the New, Disturbed, Hoobastank, Incubus, Korn, Manic Street Preachers, Mudvayne, Nickelback, A Pale Horse Named Death, Puddle of Mudd, Queens of the Stone Age, Rains, Seether, Skunk Anansie, Smile Empty Soul, Stone Sour, Tantric, Taproot, and Theory of a Deadman. Metallica said they have always wanted to tour with the band, citing Alice in Chains as a major inspiration for their 2008 release, Death Magnetic. Alice in Chains has also had a significant influence on modern heavy metal. Their songs were covered by various metal bands such as In Flames, Opeth, Dream Theater, Secrets of the Moon, Suicide Silence, 36 Crazyfists, Cane Hill, Ektomorf, Dritt Skitt, Grave and Thou, who described their 2018 EP Rhea Sylvia as "a melodic grunge, Alice in Chains homage." In 2009, Anders Fridén of Swedish melodic death metal band In Flames cited Layne Staley as an inspiration for his vocals on the band's later albums. In addition to fellow musicians, the band has also received praise from critics, with Steve Huey calling them "one of the best metal bands of the '90s" upon reviewing the 1999 compilation Nothing Safe. In 2009, the Vitamin String Quartet released the album The String Quartet Tribute to Alice in Chains, featuring instrumental versions on viola, violin and cello of 12 of the band's biggest hits.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.